Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
NCT06218667 · Memorial Sloan Kettering Cancer Center · PHASE1/PHASE2 · withdrawn · last registry update 2024-10-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study drug not available per sponsor” | – | Registry record, Memorial Sloan Kettering Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
- 2025-09-08Also stopped (terminated): Institut Curie, PF-05212384 (NCT02438761)
- 2025-08-08Also stopped (terminated): Fondazione Italiana Linfomi - ETS, Copanlisib (NCT04433182)
- 2025-08-03Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Durvalumab (NCT03842228)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
- 2025-07-11Results posted on the registry: M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2025-06-15Also stopped (withdrawn): VA Office of Research and Development, copanlisib + Avelumab (NCT05687721)
- 2025-05-31Results posted on the registry: Bryan Schneider, MD, Capecitabine + Talazoparib (NCT04849364)
- 2025-05-31Also stopped (terminated): Bryan Schneider, MD, Capecitabine + Talazoparib (NCT04849364)
- 2025-05-26Also stopped (terminated): Mayo Clinic, Belinostat + Carfilzomib (NCT03432741)
- 2025-05-22Also stopped (withdrawn): Inhye Ahn, Ibrutinib + Copanlisib (NCT04685915)
- 2025-04-16Results posted on the registry: National Cancer Institute (NCI), Copanlisib (NCT06400238)
- 2025-04-16Results posted on the registry: National Cancer Institute (NCI), Copanlisib (NCT06360588)
- 2025-04-10Results posted on the registry: Inova Health Care Services, Biopsy-Guided Therapy Selection (NCT04965688)
- 2025-04-10Also stopped (terminated): Inova Health Care Services, Biopsy-Guided Therapy Selection (NCT04965688)
- 2025-03-24Results posted on the registry: Kazia Therapeutics Limited, Paxalisib (GDC-0084) (NCT03522298)
- 2025-03-04Results posted on the registry: Columbia University, Copanlisib (NCT04750941)
- 2025-03-04Also stopped (terminated): Columbia University, Copanlisib (NCT04750941)
- 2025-02-28Results posted on the registry: Memorial Sloan Kettering Cancer Center, Vemurafenib + Copanlisib (NCT04462471)
- 2025-02-10Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Placebo (NCT04589650)
- 2025-01-24Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Placebo (NCT06790693)
- 2025-01-08Results posted on the registry: Genentech, Inc., Entrectinib + Inavolisib (NCT04632992)
- 2025-01-03Phase 3 first posted: Celcuity Inc, Arm A: Gedatolisib + Palbociclib + Fulvestrant + Arm B: Ribociclib + Fulvestrant (NCT06757634)
- 2024-12-11Results posted on the registry: Bayer, Copanlisib (BAY80-6946) + Placebo (NCT02626455)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision